Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...

Pfizer's COVID vaccine (Comirnaty) is fully approved for patients ages 12 and up, and authorized for kids ages 6 months through 11 years. Novavax's COVID shot (Nuvaxovid) is fully approved for people ...

The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., who has pushed for changes around mRNA ...

The government’s top vaccine official, working under Health Secretary Robert F. Kennedy Jr., restricted the approval of two COVID-19 vaccines, disregarding recommendations from government scientists.

The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots.

The latest trading day saw Novavax (NVAX) settling at $6.36, representing a -2.15% change from its previous close.

Shares of Novavax Inc. NVAX rose 2.85% to $6.49 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.43% to ...